CD276 and B-cell acute lymphoblastic leukemia: According to a study using a CD276‐CAR construct to transduce natural killer (NK)‐92 cells and CRISPR–Cas9 to knock down three different inhibitory checkpoints (CBLB, NKG2A, and TIGIT) in NK cells, triple‐knockdown CD276‐CAR‐NK‐92 cells showed a significant enhancement of toxicity against leukemia cells, and are a promising candidate for the treatment of AML and B cell acute lymphoblastic leukemia.318